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Abstract 
 
Translation elongation isoform eEF1A1 has a pivotal role in protein synthesis and is almost 
ubiquitously expressed. In mice and rats that transcription of the gene encoding eEF1A1 is 
downregulated to undetectable levels in muscle after weaning; eEF1A1 is then replaced by a 
separately encoded but closely related isoform eEF1A2, which has only previously been 
described in mammals. We now show that not only is eEF1A2 conserved in non-mammalian 
vertebrate species, but the down-regulation of eEF1A1 protein in muscle is preserved in 
Xenopus, with the protein being undetectable by adulthood.  Interestingly, though, this down-
regulation is controlled post-transcriptionally, and levels of full-length eEF1A1 mRNA 
remain similar to those of eEF1A2.  The switching off of eEF1A1 in muscle is therefore 
sufficiently important to have evolved through the use of repression operating at different 
levels in different species. The 3’UTR of eEF1A1 is highly conserved and contains predicted 
binding sites for several miRNAs, suggesting a possible method for controlling of expression. 
We suggest that isoform switching may have evolved because of a need for certain cell types 
to modify the well-established non-canonical functions of eEF1A1.  
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Introduction 
 
The translation elongation factor eEF1A is essential for protein synthesis. It delivers 
aminoacyl tRNAs to the A site of the ribosome in a GTP-dependent fashion. In mammals, 
there are two isoforms, eEF1A1 and eEF1A2, encoded by genes on different chromosomes; 
they are 92% identical and 98% similar at the amino acid level [1]. Both proteins are highly 
conserved, with only one amino acid difference between human and mouse eEF1A2 proteins 
[2].  The two proteins show similar translation activities, but have different relative affinities 
for GTP and GDP, with markedly different dissociation rate constants [3]. eEF1A1 has been 
implicated in a number of other “moonlighting” or non-canonical functions (reviewed in [4]), 
including actin binding and bundling [5], apoptosis [6] and tumourigenesis [7]. eEF1A2 is 
expressed at the RNA level in brain, heart and skeletal muscle in rats [8], rabbits [3] and 
humans [1]. Similarly, at the protein level, eEF1A2 expression is seen only in the brain, heart 
and skeletal muscle of rats, humans and mice [9], with minor sites of expression in pancreatic 
islets and colon crypts [10]. Deletion of the Eef1a2 locus in mice results in the mutant wasted 
(wst) [11]. Mice homozygous for this mutation show neuromuscular defects, including a loss 
of muscle mass and neuropathological changes [12]. In humans, eEF1A2 has been shown to 
have oncogenic properties and has been implicated in ovarian and breast cancer [13, 14]. 
 
Although eEF1A1 is almost ubiquitously expressed, it is downregulated in those tissues in 
which eEF1A2 is expressed [15, 16], an effect which is seen most dramatically in muscle. In 
mouse muscle, levels of eEF1A2 mRNA increase after birth, whilst levels of eEF1A1 mRNA 
and protein decrease to undetectable levels by 25 days [9, 11] so that in this tissue at least, a 
complete switch occurs between eEF1A1 and eEF1A2. A similar situation is seen in rats, 
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with dramatic down-regulation of eEF1A1 mRNA in postnatal brain [16], muscle and heart 
[15]. 
 
There is no direct experimental evidence for an eEF1A2 orthologue in non-mammalian 
vertebrates. Indeed, in zebrafish and chicken it has been stated that only one eEF1A gene is 
present [17, 18]. In the frog Xenopus laevis, two major isoforms of eEF1A have been 
described. eEF1A-O is expressed in germ cells and early embryos [19, 20]. The somatically 
expressed eEF1A-S (the presumed orthologue of eEF1A1) was first described by Krieg et al 
[21]. It is expressed in adult liver [20] and in the germ cells of the gonad prior to 
metamorphosis [19]. At metamorphosis there is a switch from the somatic to the oocyte-
specific form in the germ cells. At the amino acid level, the eEF1A-O and eEF1A-S proteins 
are 91% identical. eEF1A-S is said to be the only somatic form of eEF1A in Xenopus [20]. In 
spite of this, bioinformatic analysis suggested the presence of eEF1A2 orthologues in other 
vertebrates, based on their sequence similarity with mammalian eEF1A2 and potential tissue 
distribution. We now present the analysis of eEF1A2 in Xenopus; as in mammals, expression 
is limited to neurons and muscle and eEF1A1 (eEF1A-S) protein is absent from adult muscle. 
Importantly, and in contrast to the situation in mammals, eEF1A1 mRNA is still found in 
adult Xenopus muscle, so the tissue-specific down-regulation of eEF1A1 in postnatal muscle 
occurs post-transcriptionally whereas in mammals the same switch is regulated at the 
transcriptional level. The 3’UTR of eEF1A1 in both X.tropicalis and X.laevis contains  highly 
conserved recognition sites for miR-133, a microRNA strongly implicated in muscle 
development [22], and we examined this miRNA as a candidate for control of eEF1A1 
expression in Xenopus.  
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Materials and Methods 
 
Frogs 
Adult female X. laevis were bred at the University of Edinburgh and the MRC Human 
Genetics Unit, Edinburgh. They were euthanized using a Schedule 1 method. Stage 17, 25, 35 
and 42 embryos were also obtained from the University of Edinburgh, and adult X. tropicalis 
muscle was obtained from the National Insititute of Medical Research, Mill Hill, London. 
 
Bioinformatics 
The mouse eEF1A2 mRNA sequence was used to search nucleotide databases at NCBI using 
BLAST. ClustalW analysis was performed using EBI services 
(http://www.ebi.ac.uk/clustalw/index.html) followed by Boxshade analysis 
(http://www.ch.embnet.org/software/BOX_form.html).  
 
mRNA RT-PCR 
The RNeasy Midi kit (Qiagen) was used to extract RNA from 150mg xenopus tissue, as per 
the manufacturer’s instructions. The recommended modifications for extracting RNA from 
muscle were observed. RNA was reverse-transcribed using the Retroscript kit (Ambion). 
eEF1A2 PCR primers used in figure 2 were as follows: forward: 5’-
GAAGGAAGGCAATGCAAAT-3’; reverse: 5’-TGCAGTATGGCAGTCAATA-3’. Primers 
used to amplify X. tropicalis eEF1A2 were: forward; 5’-TCGACAAAAGGACGATAGAG-
3’; reverse: 5’- ATTGATTCCCACAATGAGGC-3’. Those used for X. tropicalis eEF1A1 
were: forward; 5’-TCGACAAGAGAACCATCGAA-3’; reverse; 5’-
GTTAACACCAACGATCAGT. 
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PCR primers for eEF1A1 (Figure 4) were forward: 5’-TAAAGAGGGATCTGGCAGC-3’; 
reverse: 5’-AGCAGTGTGACAATCCAAC-3’. Each reaction contained 5mM forward and 
reverse primers, 0.05mM dNTPs, 1.485M betaine (Sigma) and 1l of either the reverse-
transcribed or no-RT control RNA mixes, in a total volume of 50l. Conditions were 950C 
for 3 minutes, followed by 40 cycles for eEF1A2 and 30 cycles for eEF1A1 of 940C for 30 
seconds, 480C for 30 seconds and 720C for 30 seconds, followed by 10 minutes at 720C, on 
an MJ Gradient Cycler. Full-length eEF1A1 was generated using the Expand High-Fidelity 
Plus kit (Roche), according to the manufacturer’s instructions, with an annealing temperature 
of 500C on an MJ Gradient Cycler. Primers used were: forward: 5’- 
AATCCACAATGGGAAAGGAA-3’; reverse: 5’-TTGGTCAAGTTGCCTCCCAC -3’.  
 
mRNA Real-time PCR 
Real-time PCR analysis was performed on a Bio-Rad MyIQ using the following primers: 
eEF1A2 forward: 5’-GAAGGAAGGCAATGCAAAT-3’; reverse: 5’-
GCTTTAGAATGCCGGTC-3’; eEF1A1: forward: 5’- AGGCTCCTTCAAGTATGCCT-3’; 
reverse: 5’-ATGCTCACGGGTTTGTCCAT-3’. Rpl8 was used a reference gene, with the 
following primers: forward: 5’- TAAGCTTCGGGCTATCGACT-3’; reverse: 5’-
GTGCCAACAGGGAGTACATT-3’. Standard curves were constructed, and the data 
analysed using a modified Pfaffl method and the MyIQ software. 
 
Sequencing 
PCR products were cleaned up using ExoSapIT (USB), sequenced using Big Dye (ABgene) 
on an MJ gradient cycler, precipitated using ethanol and EDTA and analysed on an ABI 3100 
capillary sequence analyser. Primers used were as for PCR, above.  
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Western blotting 
Tissues were homogenised in 0.32M sucrose with Complete Antiprotease Cocktail (Roche) 
and quantified using the DC protein quantification system (BioRad); 15 μg total protein 
extract was electrophoresed on a 10% SDS-polyacrylamide gel. This was then blotted onto 
Hybond-P membrane (Amersham Pharmacia Biotech) for 1 hour at 15V. Membranes were 
blocked overnight in blocking buffer (25% v/v Tween 20 and 5% w/v fat free powdered milk 
in PBS), incubated in primary antibody (1:200 in blocking buffer for eEF1A2-2; 1:500 for A. 
salina antibody; 1 in 1000 for GAPDH) for 1.5-2 hours, washed four times in PBS-T and 
incubated with secondary antibody for 1 hour at 1:500 dilution (HRP-conjugated anti-sheep, -
rabbit or -mouse; Dako). Membranes were again washed in PBS and detected using enhanced 
chemiluminesence (ECL; Amersham Biosciences) according to the manufacturer’s 
instructions. The eEF1A2-2 antibody was generated in-house (13), the A. salina antibody was 
previously described by Sanders et al. [23], and the GAPDH antibody was from Millipore. 
 
Immunohistochemistry 
Tissues were fixed in 4% (w/v) paraformaldehyde for approximately 2 hours, paraffin-
embedded and 4μm sections cut. Slides were rehydrated through a graded series of ethanols, 
subjected to antigen retrieval by microwaving at full power for 15 minutes in 0.01M citric 
acid (pH 6.0), cooled, washed in H20 and then treated in 3% v/v hydrogen peroxide for 10 
minutes. They were again washed in H20, washed in PBS for 5 minutes, and blocked in rabbit 
serum for 10 minutes (1:5 in PBS; Sigma). They were then incubated in anti-eEF1A2 
antibody (1:100 in PBS), washed twice in PBS, incubated for 30 minutes in biotinylated anti-
sheep antibody (1:500 in PBS; Vector), and finally incubated in StreptABC (Dako) for 30 
minutes. They were again washed in PBS, and then incubated in diaminobenzidene (DAB; 
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Vector) for approximately two minutes. Slides were counterstained with haematoxylin 
(Surgipath), dehydrated and mounted in pertex (CellPath).  
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Results 
 
Initially we used BLAST to identify X. laevis ESTs which showed higher similarity to mouse 
eEF1A2 than to any other mammalian elongation factor, or any of the known Xenopus 
elongation factors. Subsequently, sequences have been deposited in NCBI for full-length 
cDNAs corresponding to X.laevis eEF1A2 (e.g. BC054279). ClustalW analysis of eEF1A1 
and eEF1A2 protein sequences from X. laevis, X. tropicalis and mouse show two distinct 
clusters of sequences; those corresponding to eEF1A1, and those corresponding to eEF1A2. 
Mouse eEF1A1 and mouse eEF1A2 differ at 34 positions out of 463; of these differences, 22 
are wholly conserved such that eEF1A2 from all three species has the same amino acid, as 
does eEF1A1 at the equivalent position (figure 1).  
 
Using RT-PCR on RNA from a range of tissues from adult X. laevis, we analysed the 
expression pattern of eEF1A1 and eEF1A2 at the mRNA level. eEF1A2 was found in the 
tissues that would be predicted from analysis of the gene in mammals; that is, brain, muscle 
and heart (figure 2, panel A), suggesting that the putative X. laevis eEF1A2 is indeed a 
genuine orthologue of mammalian eEF1A2. eEF1A1 mRNA, unexpectedly, was present in 
all tissues examined, including adult muscle (figure 2 panel A). In order to confirm the 
specificity of the PCR, the products were sequenced. The sequence obtained was identical to 
the published eEF1A1 (eEF1A-S) sequence. Further PCR primers were used to amplify all 
regions of the gene; all were sequenced, and all corresponded to the published sequence (data 
not shown). 
 
We then went on to analyse expression of the two genes at the protein level. Using an anti-
eEF1A2 antibody we have generated (eEF1A2-2; [10, 14]), we show that eEF1A2 protein is 
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expressed in the same tissues as eEF1A2 mRNA (figure 2 panel B), that is, central nervous 
system (brain, spinal cord, optic ganglion) and muscle. No eEF1A2 was seen in liver, gall 
bladder, lung, kidney or spleen. We used a further antibody, eEF1A2-1, to investigate which 
cell-types express eEF1A2 using immunohistochemistry (figure 2 panel C). In the brain and 
spinal cord, expression was restricted to large neurons and localised to the cytoplasm, as seen 
in mammals [10]; strong staining was also seen in cardiac muscle.  
 
We then analysed expression by Western blotting. The samples shown in figure 2 were run 
simultaneously on duplicate gels, and the top panel Western shows eEF1A1 expression. We 
used an antibody raised against eEF1A from Artemia salina and found that it specifically 
recognised X. laevis eEF1A1 based on its reciprocal expression pattern with eEF1A2. 
eEF1A1 was expressed in all tissues examined, except adult muscle and optic ganglion 
(figure 2 panel B). All those samples that were negative for eEF1A1 were positive for 
eEF1A2, showing that the protein was present, with the exception of lung which came up 
negative for both eEF1A1 and eEF1A2. As in mammals, both eEF1A1 and eEF1A2 are 
found in whole extracts of brain and spinal cord. Thus, in X. laevis, the expression pattern of 
eEF1A1 at the protein level is the same as that seen in mammals, notably the absence of 
expression in adult muscle, in contrast to the results found at the RNA level.  
 
To confirm that a full-length eEF1A1 transcript is generated in muscle long-range PCR was 
used to amplify the complete 1.6 kb transcript (figure 3 panel A).  This too was sequenced, 
and again the sequence was identical to that of eEF1A1. We then wanted to rule out the 
possibility that the discrepancy between the RNA and protein results were due to obvious 
sensitivity differences between Western blotting and RT-PCR. Real-time PCR analysis was 
performed on cDNA generated from X. laevis liver and muscle. Whilst levels of eEF1A2 
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were undetectable in liver, levels of eEF1A1 and eEF1A2 mRNA were similar in muscle 
(figure 3 panel B), showing that if the transcript in muscle was being translated into a stable 
protein it would have been easily detectable by Western blotting. 
 
As X. laevis are allotetraploid, any analysis could be complicated by the presence of 
paralogues, so we went on to establish whether eEF1A1 expression could be detected in 
muscle tissue from the diploid frog X. tropicalis. In adult X. tropicalis muscle, both eEF1A1 
and eEF1A2 mRNA are present (figure 3 panel C). However, as in X. laevis, at the protein 
level only eEF1A2 is present in muscle (figure 3 panel D). The post-transciptional repression 
of  eEF1A1 in muscle is therefore conserved between X. laevis and X. tropicalis. 
 
The 3’UTR of eEF1A1 is highly conserved throughout vertebrate evolution, and contains a 
predicted binding site for microRNA miR-133, which is crucial for muscle development. We 
therefore sought to establish whether the lack of eEF1A1 protein in muscle could be due to 
the actions of miR-133, potentially acting via translational repression. Since transgenesis was 
not possible, we used two Xenopus cell lines, XTC-2 [24] and A6 kidney epithelial cells, 
both of which we found to express high levels of eEF1A1 but only low levels of miR-133. 
Transfection of these cell lines with a miR-133 precursor led to many thousand fold 
upregulation of expression of miR-133 in comparison with cells transfected with a negative 
control miRNA, but had no appreciable effect on levels of eEF1A1 mRNA or protein when 
compared with cells transfected with a negative control miRNA at multiple time-points (data 
not shown).  
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Discussion 
 
We have demonstrated the presence of an orthologue of eEF1A2 (previously only described 
in mammals) in two non-mammalian vertebrates, X. laevis and X. tropicalis. As in mammals, 
expression of this eEF1A2 orthologue is confined to the central nervous system and muscle; 
within tissue from brain and spinal cord eEF1A2 is localised solely to neurons, again 
reflecting precisely the pattern seen in mammals [9, 10]. We have also demonstrated the 
absence of detectable eEF1A1 protein in adult muscle of Xenopus, again as seen in 
mammals. Unexpectedly though, eEF1A1 mRNA is still present in frog muscle, suggesting 
that downregulation of eEF1A1 has evolved through the use of a completely different 
mechanism from that in mammals. This suggests that eEF1A isoform switching in muscle is 
of critical importance for postnatal development. In mammals, regulation is almost entirely 
transcriptional. eEF1A1 mRNA is not detectable in adult mouse muscle by RT-PCR [11], or 
in rabbit muscle by Northern analysis [3]. In rat muscle, eEF1A1 is barely detectable by 30 
days using RNase protection and Northern analysis [15]. By contrast, in both X.laevis and X. 
tropicalis, eEF1A1 mRNA is still present in abundance. Indeed the level of eEF1A1 mRNA 
in muscle is the same as that seen for eEF1A2 in muscle as measured by qPCR. The post-
transcriptional regulatory mechanism seen in Xenopus species has clearly been quite strongly 
conserved, since estimates for the time of the X.tropicalis/laevis divergence range up to 110 
mya. The mechanism by which eEF1A1 is regulated at the post-transcriptional level in 
Xenopus adult muscle is as yet unknown, and precise determination of the mechanism would 
be technically challenging, requiring transgenesis experiments followed by assays in fully 
developed animals.  
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One possible explanation is that the highly conserved 3’UTR of eEF1A1, which shows no 
similarity with that of eEF1A2, is targeted by muscle-specific miRNAs. An attractive 
candidate was miR-133, but expression of precursor miR-133 resulting in the upregulation of 
both miR-133a and 133b in Xenopus cell lines failed significantly to affect the level of 
eEF1A1 mRNA in these cells. It is still conceivable that this miRNA is involved in the 
control of eEF1A1 expression in mature Xenopus muscle, but this would be harder to 
evaluate. 
 
If the lack of expression was mediated at the level of translational repression then a candidate 
element would be the terminal oligopyrimidine (5’TOP) sequence which has been shown to 
be present in the 5’UTR of X.laevis eEF1A1 mRNA [25]. Control through the 5’TOP 
sequence in muscle might be expected to result in down-regulation of all 5’TOP-containing 
transcripts; this would presumably not occur in normal muscle since transcripts encoding 
most ribosomal components contain 5’TOPs. The transcriptional start site for xenopus 
eEF1A2 has not been determined, but there is no indication of anything more than a very 
short oligopyrimidine tract in the published cDNA sequence. An alternative mechanism 
would be the binding of a muscle-specific RNA-binding protein to the eEF1A1 transcript, 
resulting in suppression of translation. An attractive candidate for such a binding protein is 
the fragile X-related protein FXR1. It has been shown that eEF1A1 mRNA from Xenopus 
binds to the FMR1 protein, and that this binding is mediated through the RGG and KH2 
domains of the protein [26]. FMR1, however, is widely expressed and is therefore unlikely to 
be mediating a muscle-specific down-regulation of eEF1A1. FXR1 on the other hand shares 
both the RGG and KH2 domains with FMR1 and is highly expressed in X. tropicalis muscle 
[27]; indeed, its expression pattern is very reminiscent of that of eEF1A2, as would be 
expected of a protein involved in eEF1A1 repression.  
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We hypothesise that frog muscle, with the growth and death programs that have to be 
executed during metamorphosis, has a need for a rapid-response mode of control of eEF1A1 
expression, and that this is the reason for a post-transcriptional control mechanism operating 
in Xenopus species. The fact that eEF1A1 down-regulation during muscle differentiation 
occurs widely in vertebrates, and yet is controlled through completely different mechanisms 
in different species, suggests that eEF1A type switching is crucial for certain cell types. 
Although it is possible that the different properties of eEF1A1 and eEF1A2 relate solely to 
their activity in protein synthesis, it seems likely that the requirement for eEF1A-type 
switching relates to the moonlighting roles of eEF1A1 such as cytoskeletal remodelling, and 
the need for muscle and neuronal cells to avoid or to modify these moonlighting properties. 
The observation that eEF1A2 is expressed with such a restricted tissue distribution in such 
diverse species suggests that there may be a real need to avoid its expression in a wider 
context, tying in with the identification of eEF1A2 as a potential oncogene. 
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Figure legends 
 
Figure 1 
Figure 1 shows the results of ClustalW analysis of eEF1A1 and eEF1A2 from X.laevis, 
X.tropicalis and mouse; the results were coloured using Boxshade. Xt is Xenopus tropicalis, 
Xl is Xenopus laevis, m is mouse; 1A1 is eEF1A1, 1A2 is eEF1A2. An asterisk denotes the 
position of the serine residue present in eEF1A2 from all species that is predicted to be a 
phosphorylation site. 
 
Figure 2 
Panel A: RT-PCR of eEF1A1 (top panel) and eEF1A2 (bottom panel) in RNA from a range 
of tissues taken from adult X.laevis. Li= liver, Lu= lung, S= spleen, O= oocytes, G= gall 
bladder, B= brain, H= heart, M= muscle (two independent tissue samples). No-RT controls 
were carried out and were negative for all tissues for both genes (data not shown). 
  
Panel B: Western blots of eEF1A1 (top) and eEF1A2 (bottom). Gels were run in duplicate 
using the samples of same protein extract at the same time. Og= optic ganglion, B= brain, 
Sc= spinal cord, M= muscle, Li= liver, G= gall bladder, Lu= lung, K= kidney, S= spleen.  
 
Panel C: Immunohistochemistry for eEF1A2 on spinal cord and cardiac muscle from X. 
laevis, together with negative controls. eEF1A2 shows widespread expression in cardiac 
muscle but is expressed in only in neuronal cells in spinal cord. 
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Figure 3 
Panel A: RT-PCR of eEF1A1 in X.laevis muscle and liver using primers that amplify full-
length mRNA. Lanes labelled with – are no-RT controls. 
 
Panel B: Real-time RT-PCR results for eEF1A1 and eEF1A2 in liver (showing expression of 
eEF1A1 only) and muscle (showing equal levels of expression of eEF1A1 and eEF1A2). 
Units of expression are relative to the internal control, Rpl8. 
 
Panel C: Analysis of expression of eEF1A1 in adult muscle from X.tropicalis. B shows RT-
PCR of eEF1A1 and eEF1A2 in muscle from X. tropicalis (Xt) and X.laevis (Xl) together 
with negative controls (-RT). All PCR products are of the predicted size.  
 
Panel D: two Western blots, run in parallel, for eEF1A1 and eEF1A2. M(t) is muscle tissue 
from X.  tropicalis, M(l) is muscle tissue from X.  laevis and L(l) is liver from X. laevis.  
 
 
 
 
 
 
 
 
